Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRT106 in Locally Advanced or Metastatic Solid Tumors
NCT06368921Phase 1Recruiting
- Sponsor
- Guangzhou Virotech Pharmaceutical
- Start
- Jun 2024
- Primary completion
- Sep 2027
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VRT-106 in solid tumor, sponsored by Guangzhou Virotech Pharmaceutical. Primary endpoints: Safety and tolerability of escalating doses at 2 years and Maximum Tolerated Dose or Recommended Phase 2 Dose at 2 years. Started Jun 2024; status: recruiting.
02
Drugs
VRT-106
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06368921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06368921.